Recently, DPP4 is a potential receptor for entry of SARS‐CoV‐2, and DPP4 inhibitors might be a potential therapeutic strategy in treating COVID‐19 even in nondiabetic patients130, 131 (Figure 2). Here, DPP4 is linked to COVID-19.